ライフサイエンスコーパス: erythema

1 es exhibited a clinical score of 1 (pinpoint erythema).

2 rized by epidermal hyperplasia, scaling, and erythema.

3 mall and medium joint pain, without edema or erythema.

4 ndoscopy showing areas of nonspecific patchy erythema.

5 AEs were application-site reactions, usually erythema.

6 nt is often initiated by symptoms or visible erythema.

7 , consisting mainly of infusion syndrome and erythema.

8 ced more TTs than UVA1 for the same level of erythema.

9 lmarked by undermined borders and peripheral erythema.

10 ft breast with no skin retraction, edema, or erythema.

11 eukocyte markers, while quantifying clinical erythema.

12 on site pain and tenderness, induration, and erythema.

13 delivery, but are sometimes associated with erythema.

14 pital because of cough, sputum, pruritus and erythema.

15 ility and reproducibility for both scale and erythema.

16 0%]), alopecia (18 [19%] vs eight [4%]), and erythema (18 [19%] vs five [3%]).

17 and as tenderness (33 [66%] of 50 [51-79]), erythema (20 [40%] of 50 [26-55]), and pruritus (41 [82%

18 local adverse events with imiquimod included erythema (27%), scabbing or crusting (21%), flaking (9%)

19 mon adverse events were again injection-site erythema (33 [8%] of 416 with 50 mg sirukumab every 4 we

20 the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group) and nasopharyn

21 ory tract infection (8%), and injection-site erythema (6%).

22 eported injection site pain (52% vs 17%) and erythema (73% vs 25%) more frequently than placebo recip

23 acterized by less transient and nontransient erythema, a more lateral distribution of erythema and te

24 int scale of plaque thickening, scaling, and erythema; a score of 0 indicates clear, 1 almost clear,

25 ter an immediate allergic reaction including erythema, abdominal pain, vomiting, and anaphylactic sho

26 , 28-53 years of age), the mean reduction in erythema across six doses of UVR (300-800 mJ/cm(2) in 10

27 A 35-year-old male presented with erythema and burning pain in the hands since early child

28 inant, disorder characterized by generalized erythema and cutaneous blistering at birth followed by h

29 Clinical examination exhibited erythema and enlargement of the interdental papillae bet

30 erized by recurrent episodes of palmoplantar erythema and epidermal peeling.

31 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 212 patients (23

32 (100g), he experienced nausea, wheezing, and erythema and had visited our hospital.

33 in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2.5 g ida

34 enotype consisting of early-onset patches of erythema and hyperkeratosis, as well as SCA manifesting

35 ed cutaneous immunity based on the extent of erythema and induration after intradermal VZV antigen in

36 Transient erythema and induration were more common after intraderm

37 Old human subjects exhibited decreased erythema and induration, CD4(+) and CD8(+) T-cell infilt

38 Erythema and intense scratching developed 2-3 days befor

39 measurements confirmed the absence of local erythema and irritation.

40 s shown by the action spectra of UVR-induced erythema and nuclear DNA (nDNA) damage.

41 Erythema and oedema were more frequent with avotermin th

42 Low-grade erythema and pain at the injection site were the most co

43 d on the day of treatment, and short-lasting erythema and pain at the site of application were common

44 IPA increases skin blood flow without erythema and PG increased erythema with decreased skin b

45 scar thickness; and reflectometry to measure erythema and pigmentation.

46 ed to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and s

47 The median overall score combining erythema and roughness/bumpiness was 3.0 (IQR, 2-4) for

48 for association with skin cGVHD involvement (erythema and sclerosis, skin symptoms), lacrimal dysfunc

49 he spontaneous behaviors, in addition to the erythema and skin pathology, were markedly improved.

50 haracterized by intermittent flares of pain, erythema and swelling in and around the joints, which ar

51 Facial erythema and telangiectasia are commonly associated with

52 Participants with ETR tended to have erythema and telangiectasia primarily on the central fac

53 ent erythema, a more lateral distribution of erythema and telangiectasia, less neurogenic mast cell a

54 Complete treatment of erythema and texture in KP may require diode laser treat

55 the cessation of spread of infection-related erythema and the absence of fever at 48 to 72 hours.

56 esponse (healing of erosions, improvement in erythema, and alleviation of pain), adverse effects, and

57 dema, lupus erythematosus [occurring twice], erythema, and dermohypodermitis all experienced by one [

58 sorders associated with generalized scaling, erythema, and epidermal barrier impairment.

59 Presence of epithelial desquamation, erythema, and erosions on gingival tissue is usually des

60 nces in vaccination take rates, lesion size, erythema, and induration or in serum neutralizing-antibo

61 Pain, swelling, erythema, and itching were the most commonly reported lo

62 ical diagnosis based on intermittent warmth, erythema, and pain in the distal extremities.

63 ical diagnosis based on intermittent warmth, erythema, and pain in the distal extremities.

64 Alopecia, injection site erythema, and pruritus were 13%, 27%, and 10%, respectiv

65 ies and were often associated with swelling, erythema, and pruritus.

66 disease (higher and more sustained viremia, erythema, and thrombocytopenia).

67 uman-like disease, including fever, viremia, erythema, and thrombocytopenia.

68 is, grade 1 erythema multiforme, and grade 3 erythema; and grade 2 infusion-related reaction.

69 ned as a >=20% reduction of lesion spread of erythema area at the primary infection site at 48 to 72

70 edema in mice, and reduced susceptibility to erythema arising from narrow-band 311-nm UVR in humans.

71 EtOH and ButOH increase erythema as a function of skin blood flow.

72 r the sunburn threshold or the resolution of erythema, as assessed by spectrophotometric hemoglobin i

73 cterized by keratinocyte hyperproliferation, erythema, as well as a form of pruritus, involving cutan

74 safely treat skin inflammation, scaling, and erythema associated with psoriasis while avoiding possib

75 dpoint was a >/=20% reduction in the area of erythema at 48-72 hours in the intent-to-treat populatio

76 were reported aside from mild and transient erythema at site of treatment.

77 uncommon but included discomfort, cutaneous erythema, blistering, eyelash loss, and floaters; these

78 sers have been used to reduce the associated erythema but not the textural irregularity.

79 tamin D(3) synthesis is small, compared with erythema, but that this difference may be sufficient to

80 Findings included eyelid swelling and erythema, conjunctival chemosis, pain on eye movement, m

81 rate cutaneous inflammation characterized by erythema, dermal infiltrates of CD45(+) leukocytes, and

82 Impact on skin erythema, dermal leukocytic infiltration, and concentrat

83 Subsequently, a dose-related erythema developed at treatment sites by 3 hours and per

84 ( Fig 1 ), there was generalized periareolar erythema, dimpling, firmness, and fixation involving the

85 irradiated with UVB (three times, 1 minimal erythema dose (80 mJ/cm(2)), weekly) for 10 weeks, and e

86 Minimal erythema dose (MED) and melanin index were determined us

87 -UVB) regimens start with 70% of the minimal erythema dose (MED) with 20% increments at each treatmen

88 s that measured time-related UVR in standard erythema dose (SED) and corresponding sun diaries (mean,

89 rotein changes in the skin after one minimal erythema dose of spectrally pure UVA1 (50 J cm(-2)) and

90 in vivo by looking at changes in the minimal erythema dose with subsequent doses of UV radiation.

91 ion, median (IQR) sunburn threshold (minimal erythema dose) was 28 (20-28) and 20 (20-28) mJ/cm(2) in

92 during the study was 39.1 (30.9) as standard erythema dose, comparable to a quarter of the median sum

93 uence the 24 hour minimal phototoxic dose or erythema dose-response.

94 exposures ranging from 0.65 to 3.9 standard erythema doses (SEDs), which were equivalent to 15-90 mi

95 n between our subjects' UVB and UVA1 minimal erythema doses implies that UVA1 and UVB erythema occur

96 or imiquimod, reduced the inflammation from erythema doses of artificial sunlight, and lowered the t

97 Rash or erythema due to APM was reported in 7 (37%) patients, al

98 nically important differences in tendency to erythema during a standard 70/20% NB-UVB twice-weekly re

99 Side effects, including the development of erythema during phototherapy, were similar for the two l

100 Topically applied PAO induces cutaneous erythema, edema and micro-blisters.

101 ats exhibited a clinical score of 2 (diffuse erythema/edema).

102 narof leads to compound-driven reductions in erythema, epidermal thickening, and tissue cytokine leve

103 was related to documented EDEL (category 1: erythema/erosion; category 2: ulcer).

104 No epithelial erythema, erosions, or ulcerations were seen.

105 trichomegaly, eyelash hypertrichosis, eyelid erythema, eyelid edema, eyelid hyperpigmentation, high u

106 Thus, erythema following alcohol exposure is alcohol type spec

107 common after intradermal administration (31% erythema for full subcutaneous dose and 77% for intrader

108 se events in this period were injection-site erythema (four [1%] with placebo, 22 [8%] with 50 mg sir

109 Pulsed-dye laser was used for pruritus and erythema; fractional CO2 laser was used for stiffness an

110 VA protection, especially against cumulative erythema from repeated suberythemal exposure.

111 eria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no

112 ommon adverse events were diarrhoea, rash or erythema, hepatic adverse events, and neutropenia (not r

113 apy with positive effects on scar thickness, erythema, hydration, and elasticity.

114 s: fever, dehiscence, foul smell, peri-wound erythema, hypotension, and leukocytosis.

115 Area Severity Index (IASI), which integrates erythema (IASI-E) and scaling (IASI-S); transepidermal w

116 ticipants (78%) in the umbrella group showed erythema in 1 or more sites vs 10 of the 40 participants

117 uodenoscopy revealed asymptomatic esophageal erythema in 5 patients.

118 Notable adverse events included erythema in both groups and minor infections and nausea

119 nvestigated UV-induced sunburn apoptosis and erythema in mouse skin as a function of circadian time.

120 GE(2), PGF(2alpha), and PGE(3) accompany the erythema in the first 24-48 h, associated with increased

121 ymptoms mimicking SCAR, including hair loss, erythema, increase of inflammatory lymphocytes in the sk

122 All cases presented with pain and periocular erythema increasing over approximately 1 week.

123 h no difference in AUC analysis for measured erythema index after a geometric series of 10 UVR doses.

124 xtensively evaluated in vivo as a measure of erythema induced in human skin and is expressed as Sun P

125 asured by dermal microdialysis and cutaneous erythema), induces an intense epidermal infiltrate of ma

126 There were more local reactions (pain, erythema, induration, and warmth) and systemic reactions

127 of human diseases, including fifth disease (erythema infectiosum) in children and pure red cell apla

128 trick skin types I through III, but baseline erythema is not improved.

129 Keratolytic winter erythema (KWE) is a rare autosomal-dominant skin disorde

130 over 3 mo did not significantly reduce skin erythema, leukocyte infiltration, or eicosanoid response

131 aracterized by transient figurate patches of erythema, localized or generalized scaling, and frequent

132 lar pain (100%), sleep disturbances (75.3%), erythema migrans (59.7%), headache (46.8%), fatigue (44.

133 ri DNA in skin samples from 90 patients with erythema migrans (EM) and in synovial fluid (SF) from 63

134 fection causes an initial skin lesion called erythema migrans (EM) in human Lyme disease and in model

135 ent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesi

136 hese inflammatory responses in patients with erythema migrans (EM) or Lyme arthritis (LA) to elucidat

137 l manifestation of early Lyme disease is the erythema migrans (EM) skin lesion that develops at the t

138 urgdorferi genotypes have been isolated from erythema migrans (EM) skin lesions in patients with Lyme

139 bjective was to obtain data on patients with erythema migrans (EM) who have symptoms/signs suggesting

140 ltiplex assays in the serum of patients with erythema migrans (EM), joint fluid of patients with Lyme

141 stage LD but is insensitive in patients with erythema migrans (EM), the most common manifestation of

142 ) of 12 particular symptoms in patients with erythema migrans (n = 52) differed from matched control

143 symptoms was compared between patients with erythema migrans and 81 control subjects without a histo

144 confirmed early LD, based on the presence of erythema migrans and documentation of seroconversion or

145 course of oral doxycycline for treatment of erythema migrans and for a 14-day course for treatment o

146 5 consecutive patients with the diagnosis of erythema migrans and reported original data regarding th

147 variability in the clinical presentation of erythema migrans and the need to factor in multiple comp

148 Patients with erythema migrans and underlying hematological malignancy

149 Lyme disease patients with erythema migrans are said to have post-treatment Lyme di

150 l develop an early skin manifestation called erythema migrans at the tick bite site.

151 Blood was obtained from patients with erythema migrans before (n = 29) and 2 months after (n =

152 from 17 patients who received a diagnosis of erythema migrans between 1991 and 2011 and who had 22 pa

153 ive for B. burgdorferi DNA in a patient with erythema migrans early during therapy and in a patient w

154 ypically at least 10% of adult patients with erythema migrans experience persistence of at least 1 su

155 ent evidence supports treating patients with erythema migrans for no longer than 10 days when doxycyc

156 of the early steps of Borrelia invasion and erythema migrans formation after tick bite.

157 0-day doxycycline treatment in patients with erythema migrans has been assessed in the United States

158 ents with early Lyme disease associated with erythema migrans have a positive blood culture based on

159 Our data show that repeat episodes of erythema migrans in appropriately treated patients were

160 Erythema migrans is the most common clinical manifestati

161 Erythema migrans is the most common manifestation of Lym

162 Lyme disease as either a clinician-diagnosed erythema migrans lesion or a positive standard 2-tiered

163 dorferi genotypes in cells and patients with erythema migrans or Lyme arthritis.

164 the frequency of nonspecific symptoms among erythema migrans patients was similar to that among cont

165 arious MTTT protocols in patients with acute erythema migrans ranged from 36% (95% confidence interva

166 teins shed in the urine of patients with (1) erythema migrans rash and acute symptoms, (2) post treat

167 bite from an Ixodes scapularis tick and the erythema migrans rash associated with Lyme disease.

168 r of acute symptoms and the pattern of their erythema migrans rash.

169 nical criteria, including the presence of an erythema migrans rash.

170 9 (MMP-9) was selectively upregulated in the erythema migrans skin lesions of patients with acute Lym

171 afzelii, or Borrelia garinii recovered from erythema migrans skin lesions of patients with Lyme borr

172 patients with culture-confirmed episodes of erythema migrans to distinguish between relapse and rein

173 Concomitant erythema migrans was registered in 104 of 144 patients (

174 Patients with multiple erythema migrans were almost uniformly culture positive

175 one of the 22 paired consecutive episodes of erythema migrans were associated with the same strain of

176 study assessed whether repeated episodes of erythema migrans were due to the same or different strai

177 Patients with erythema migrans were more likely than matched control s

178 Similarly, serum samples from patients with erythema migrans who were infected with the RST1 genotyp

179 Adult patients with erythema migrans with a positive skin or blood culture f

180 s with probable LD, based on the presence of erythema migrans without documented seroconversion or of

181 86 antibiotic-treated European patients with erythema migrans, 45 with post-Lyme symptoms and 41 with

182 urteen-day antibiotic treatment, as used for erythema migrans, is effective.

183 No studies included patients without erythema migrans, so specificity data and likelihood rat

184 Among 311 patients with erythema migrans, the frequency of coinfection with HGA

185 Erythema migrans, while not pathognomonic, is the most c

186 ed with longer illness duration and multiple erythema migrans.

187 eatment-matched immunocompetent persons with erythema migrans.

188 a large (>/=5-cm diameter) rash, known as an erythema migrans.

189 ents after completing antibiotic therapy for erythema migrans.

190 s with early Lyme disease who presented with erythema migrans.

191 Lyme disease was defined by the presence of erythema migrans.

192 received standard courses of antibiotics for erythema migrans.

193 among adult European patients with solitary erythema migrans.

194 d from patients with consecutive episodes of erythema migrans.

195 re evaluated in adult European patients with erythema migrans.

196 hly sensitive by itself for the diagnosis of erythema migrans.

197 ination characteristics for the diagnosis of erythema migrans.

198 rom 57 patients with a clinical diagnosis of erythema migrans.

199 h a compatible clinical syndrome but without erythema migrans.

200 City with early Lyme disease associated with erythema migrans; it is the largest number of borrelial

201 determined using serum from 55 patients with erythema migrans; specificity was determined using serum

202 s were well tolerated in the skin, with mild erythema, minimal wheal formation and complete resolutio

203 -independent, cascade of events resulting in erythema, mixed dermal infiltrate, and epidermal hyperpl

204 Injection site pain, itching, and erythema (mostly mild) were the only solicited adverse e

205 pothyroidism; grade 3 iridocyclitis, grade 1 erythema multiforme, and grade 3 erythema; and grade 2 i

206 eumonitis, localized myositis, folliculitis, erythema multiforme, or ophthalmological manifestations.

207 n in other closely related syndromes such as erythema multiforme, Stevens-Johnson syndrome, and toxic

208 on-eczematous contact dermatitis include the erythema multiforme-like, the purpuric, the lichenoid, a

209 een administration routes for injection-site erythema (n=10 [12%] and n=0, respectively) and nausea (

210 ts in the vitespen group were injection-site erythema (n=158) and injection-site induration (n=153).

211 rface area and UVB exposure dose, related to erythema, necessary to achieve a given level of vitamin

212 nodes (3.7%-9.0%), hyperhidrosis (<2%), and erythema nodosum (<2%) were particularly suggestive of f

213 ed oral ulcers (100%), genital ulcers (62%), erythema nodosum (46%), and papulopustular lesions (54%)

214 Unlike erythema nodosum (EN) and pyoderma gangrenosum (PG), LCV

215 ease course (Pcombined = 5.94 x 10(-7)), and erythema nodosum (Pcombined = 2.27 x 10(-6)), respective

216 osition -308 was found to be associated with erythema nodosum in Caucasian sarcoidosis patients (stud

217 a gene adjacent to TNF, was associated with erythema nodosum in female Caucasian sarcoidosis patient

218 rcoidosis and may explain the higher rate of erythema nodosum in females with sarcoidosis.

219 ariant has individually been associated with erythema nodosum in sarcoidosis patients.

220 nts when evaluated before the onset of acute erythema nodosum leprosum (ENL) and persistently elevate

221 In erythema nodosum leprosum (ENL), which occurs in patient

222 pted by acute inflammatory episodes known as erythema nodosum leprosum (ENL).

223 immune reactions, reversal reaction (RR) and erythema nodosum leprosum (ENL).

224 associated with increased susceptibility to erythema nodosum leprosum in an allelic analysis, wherea

225 sal) reactions and 124 patients with type 2 (erythema nodosum leprosum) reactions.

226 s "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical

227 wn role in inflammation were associated with erythema nodosum status in 659 sarcoidosis patients and

228 noted: fever, sialadenitis, lymphadenopathy, erythema nodosum, leukocytoclastic vasculitis, transient

229 She had neither erythema nor internal organ involvements.

230 mal erythema doses implies that UVA1 and UVB erythema occur by different mechanisms.

231 ed erythema, the number of treatments before erythema occurred did not differ between skin types (P=0

232 e drug eruptions, viral exanthema, and toxic erythema of chemotherapy, Demodex folliculitis is a clin

233 tis was defined as either pus discharge with erythema of the abdominal skin or severe redness (>2 cm

234 d related to cholestatic jaundice, oedema or erythema of the extremity associated with desquamation o

235 were characterized by reversible oedema and erythema of the graft.

236 DS presents as erythema of the palatal mucosa in areas where denture-su

237 ndice, bilateral laterocervical lymph nodes, erythema of the palms, and strikingly red lips and conju

238 dmitted to our hospital because of fever and erythema on the face and extremity.

239 (aOR 5.17, 95% CI 1.9-14.1), abdominal wall erythema or discolouration at presentation (aOR 2.51, 95

240 o the absence of inflammatory signs, such as erythema or scaling.

241 n with placebo included injection site pain, erythema, or both (21 [20%] of 107 vs seven [6%] of 110)

242 se (31% prevalence) was associated with skin erythema (P < 0.001); salivary dysfunction (11% prevalen

243 over 30 years of age and is characterized by erythema, papulopustules and telangiectasia.

244 s caused by protease overactivity, including erythema, peeling, and exacerbation on water exposure.

245 Reduced UV-B means less erythema, plant damage, and slower photolysis rates.

246 r Scale (VSS), which documents pigmentation, erythema, pliability, and height, and (2) University of

247 ger than 24 hours, sometimes associated with erythema, pruritus and blisters.

248 rate transient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-relate

249 nal treatment, presence of serous discharge, erythema, purulent exudate, separation of the deep tissu

250 significantly correlated with sizes of SPT (erythema: r=0.645, urticaria: r=0.657).

251 an increase in body temperature (fever) and erythema (rash) in comparison with humanized mice inocul

252 l (ie, patch-site) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypop

253 Conjunctival erythema, redness and edema of the eyelid and an enlarge

254 ed skin blood flow (Doppler velocimeter) and erythema (reflectance colorimeter a*) following topical

255 Here we show that erythema resulting from UVR is a comprehensive and nonin

256 Ad.scIL-23-treated mice developed erythema, scales, and thickening of the skin, as well as

257 inical response to broadband UVA, comprising erythema+/-scaling plaques (17/20).

258 the dermatological sum score (DSS) assessing erythema, scaling, and plaque elevation on a 4-point sca

259 e selected based on ARC symptom severity and erythema skin prick reaction to short ragweed.

260 assessed, showing nonerosive lesions such as erythema, swelling, and lymphoid hyperplasia in 8 patien

261 palpation of her joints, without associated erythema, swelling, or crepitus.

262 enderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21).

263 ng, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more

264 Erythema symptoms induced by daily applications of imiqu

265 ainly by epidermal hyperplasia, scaling, and erythema; T helper 17 cells have a role in its pathogene

266 ve much better protection against cumulative erythema than the UVB sunscreen.

267 To our knowledge, the dusky erythema that occurred in the 3 patients described here

268 Index for Ichthyosis Severity for scale and erythema that provides (1) written descriptions of the f

269 n skin disorder of follicular prominence and erythema that typically affects the proximal extremities

270 Among patients who developed erythema, the number of treatments before erythema occur

271 UV radiation were pigmentation, scaling, and erythema; the most frequent dermoscopic changes were inc

272 d, although more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant re

273 for cancer, and ranges in severity from mild erythema to moist desquamation and ulceration.

274 rized as Kansas City classification: type 1: erythema; type 2: ulcers (2a: superficial ulcers; 2b: de

275 ation (18 [44%]), xerosis (8 [20%]), scrotal erythema/ulceration (6 [15%]), and nail splinter hemorrh

276 bcutaneous tissue, presenting with expanding erythema, warmth, tenderness, and swelling.

277 Nontransient erythema was also greater in the ETR group (50% graded m

278 the proportion of patients who had developed erythema was approximately 60% regardless of MED.

279 Erythema was assessed by eye and objectively, and the SP

280 Transient erythema was greater in the ETR group (38% graded modera

281 By contrast, the interrater reliability for erythema was higher during in-person validation compared

282 tential genetic basis for alcohol-associated erythema was investigated as the function of polymorphis

283 Moderate erythema was reported by 9 patients after DPDT and 14 pa

284 eactions occurred in most patients, but only erythema was significantly more common in the VGX-3100 g

285 Injection-site erythema was the most commonly coded term for non-seriou

286 PG-induced erythema was uniquely associated with tumor necrosis fac

287 Median length and width of erythema were 13.0 cm and 10.0 cm.

288 ptosis, inflammatory cytokine induction, and erythema were maximal following an acute early-morning e

289 hma, headache, epistaxis, and injection-site erythema) were more frequent with placebo.

290 (AEs), predominantly manifested by pruritus, erythema, wheal, or eczema.

291 ting 14g of boiled jellyfish, he experienced erythema, wheezing, nausea, and abdominal pain.

292 mild-to-moderate local reactions, primarily erythema, which rapidly resolved.

293 mild-to-moderate local reactions, primarily erythema, which rapidly resolved.

294 tly responsible for the necrolytic migratory erythema, which resolves after amino acid administration

295 was commensurate with development of palatal erythema, which suggests a role for biofilm in the infla

296 ts, one from each group, reported persistent erythema, which was considered to be possibly related to

297 signs are skin lesions (necrolytic migratory erythema), while in subjects with inactivating mutations

298 blood flow without erythema and PG increased erythema with decreased skin blood flow, all as a functi

299 ion of KLK-5 in SOD3 knockout mice exhibited erythema with increased epidermal thickness, mast cell a

300 oM) each produced perceptible induration and erythema with moderate cellular infiltration resolving w